774 results on '"Musallam, Khaled M."'
Search Results
52. Iron overload across the spectrum of non‐transfusion‐dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions
53. Cerebral infarction in β-thalassemia intermedia: Breaking the silence
54. Overall and complication‐free survival in a large cohort of patients with β‐thalassemia major followed over 50 years.
55. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia
56. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura
57. Contemporary approaches to treatment of beta-thalassemia intermedia
58. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective
59. Hypercoagulability in non-transfusion-dependent thalassemia
60. Tricuspid-valve regurgitant jet velocity as a risk factor for death in β-thalassemia
61. Thalassemia and autoimmune diseases: Absence of evidence or evidence of absence?
62. Random Forest Clustering Identifies Three Subgroups of ??-Thalassemia with Distinct Clinical Severity
63. Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II
64. Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with β thalassemia intermedia
65. Is VEGF a predictive biomarker to anti-angiogenic therapy?
66. Bone disease and skeletal complications in patients with β thalassemia major
67. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
68. A Phase 2a Study Evaluating the Safety and Pharmacokinetics (PK) of Luspatercept in Pediatric Patients with Transfusion-Dependent β-Thalassemia (TDT)
69. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study
70. The impact of zoledronic acid on regenerate and native bone after consolidation and removal of the external fixator: An animal model study
71. Renal complications in transfusion-dependent beta thalassaemia
72. Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta‐thalassemia in Taiwan: A real‐world analysis
73. 2021 update on clinical trials in β‐thalassemia
74. Molecular Spectra and Frequency Patterns of Somatic Mutations in Arab Women with Breast Cancer
75. Luspatercept for the Treatment of Anemia in Non-Transfusion-Dependent β-Thalassemia: Final Safety and Efficacy Data from the BEYOND Trial
76. Durable Symptom Improvement for Patients with Non-Transfusion Dependent Thalassemia Treated with Luspatercept: Patient-Reported Outcomes from the BEYOND Study
77. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine
78. Effects of divalproex sodium on hemoglobin level
79. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy
80. Correlation of non-mass-like abnormal MR signal intensity with pathological findings surrounding pediatric osteosarcoma and Ewing’s sarcoma
81. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major
82. Brain positron emission tomography in splenectomized adults with β-thalassemia intermedia: uncovering yet another covert abnormality
83. Ratio Between Positive Lymph Nodes and Total Excised Axillary Lymph Nodes as an Independent Prognostic Factor for Overall Survival in Patients with Nonmetastatic Lymph Node-Positive Breast Cancer
84. Primary colorectal lymphoma
85. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study
86. Ratio Between Positive Lymph Nodes and Total Excised Axillary Lymph Nodes as an Independent Prognostic Factor for Overall Survival in Patients with Nonmetastatic Lymph Node-Positive Breast Cancer
87. The wanderer: At 12 weeksʼ gestation, the patient presented with abdominal pain and a palpable mass
88. A novel genotype c.1228C>G/c.1448C-1498C (L371V/Rec-NciI) in a 3-year-old child with type 1 Gaucher disease
89. Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia
90. β-Thalassemias
91. Morbidity-free survival and hemoglobin level in non-transfusion-dependent β-thalassemia: a 10-year cohort study
92. Management of non‐transfusion‐dependent β‐thalassemia ( NTDT ): The next 5 years
93. Revisiting the non‐transfusion‐dependent (NTDT) vs. transfusion‐dependent (TDT) thalassemia classification 10 years later
94. Potential mechanisms for renal damage in beta-thalassemia
95. Smoking and the Risk of Mortality and Vascular and Respiratory Events in Patients Undergoing Major Surgery
96. Cross-Talk between Available Guidelines for the Management of Patients with Beta-Thalassemia Major
97. Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian Webthal project
98. Treating iron overload in patients with non-transfusion-dependent thalassemia
99. A liver mass in an iron-overloaded thalassaemia intermedia patient
100. Left ventricular noncompaction in patients with β-thalassemia: Uncovering a previously unrecognized abnormality
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.